Results 21 to 29 of about 55 (29)

Inhibition of neutrophilic inflammation by targeting the airway epithelial barrier with EP395.

03.03 - Mechanisms of lung injury and repair, 2022
Clive P Page
exaly   +2 more sources

EP395/#477 A Norwegian version of the gynecologic cancer lymphedema questionnaire and the lower-exteremity lymphedema screening questionnaire: translation and cross-cultural adaptation

E-Posters, 2022
Pernille Bjerre Trent, Ragnhild Sørum Falk   +1 more
exaly   +2 more sources

Late Breaking Abstract - A novel macrolide, EP395, in a LPS challenge in healthy volunteers

Airway pharmacology and treatment
Jens M Hohlfeld, Philipp Badorrek
exaly   +2 more sources

Late Breaking Abstract - A novel macrolide, EP395, in patients with stable COPD: a RCT

Airway pharmacology and treatment
Stephanie Korn, Dave Singh
exaly   +2 more sources

The new macrolide EP395 reduces airway eosinophilic inflammation.

Airway cell biology and immunopathology
Clive P Page, Yanira Riffo-Vasquez
exaly   +2 more sources

The effects of a novel macrolide glasmacinal (EP395) on alveolar macrophage phenotype and phagocytosis in COPD

Airway pharmacology and treatment
Simon Lea, Jian Li, James Baker, Jennifer Kricker, Michael J. Parnham, Dave Singh   +5 more
exaly   +2 more sources

S57 EP395, a novel non-antibiotic macrolide, enhances antiviral responses in bronchial epithelial cells from asthma patients

Impact of infection on disease mechanisms
S Malm Tillgren, M Menzel, J Kricker, MJ Parnham, V Norris, M Bech, L Uller   +6 more
exaly   +2 more sources

eP395: Calculating recurrence risk in an individual with an intrachromosomal structural rearrangement

Genetics in Medicine, 2022
Samantha Schilit, Avery Bell, Ross Rowsey, Abby Sassaman, Andrew Galinsky, Courtney Studwell, Heather Mason-Suares   +6 more
openaire   +1 more source

Macrolides and Immunomodulation: Today and the Future

Progress in inflammation research
Masaharu Shinkai
exaly